2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Rectal Neoplasms
12
Leukemia, Myeloid, Acute
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia
2
Thrombocythemia, Essential
1
Radiation Injuries
1
Primary Myelofibrosis
1
Postoperative Complications
1
Polycythemia Vera
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, B-Cell
1
Low Anterior Resection Syndrome
1
Leukemia, Myelomonocytic, Chronic
1
Hyperthermia
1
Fatigue
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Filgrastim
20
Etoposide
20
Ifosfamide
19
Cyclophosphamide
18
Vincristine
13
Radiotherapy
13
Doxorubicin
13
Peripheral Blood Stem Cell Transplantation
12
Melphalan
12
Carboplatin
10
Busulfan
9
Topotecan
8
Temozolomide
8
Magnetic Resonance Spectroscopy
8
X-Rays
6
Thiotepa
6
Phantoms, Imaging
6
Irinotecan
6
Granulocyte Colony-Stimulating Factor
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
5
trioctyl phosphine oxide
4
Mesna
4
Docetaxel
4
Dactinomycin
4
temsirolimus
3
etoposide phosphate
3
cixutumumab
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
Consolidation Chemotherapy
×
Clear all
NCT03011528
2025-11-21
CombinaiR3
Institut Curie
Phase 2
Completed
45 enrolled